What is the prevalence of Syringomyelia?

Syringomyelia is estimated to affect approximately 8.4 per 100,000 individuals, though precise global prevalence remains difficult to determine due to significant underdiagnosis and the varied underlying causes of the condition.

Epidemiological Context

Because Syringomyelia is often secondary to other structural abnormalities—such as Chiari malformations, spinal cord trauma, or tumors—it is frequently categorized as a rare disease rather than a primary diagnosis. Reliable incidence rates for Syringomyelia are challenging to establish, as many patients remain asymptomatic for years, leading to a significant gap between clinical prevalence and true population prevalence. While some literature suggests a slight male-to-female ratio variance depending on the etiology (e.g., post-traumatic vs. congenital), there is no definitive consensus that the condition disproportionately favors one gender globally.

Age and Demographics

The onset of Syringomyelia most commonly occurs in young adulthood, typically between the ages of 20 and 40. However, because it can be congenital or linked to developmental spinal issues, pediatric cases are well-documented. There are no clear geographic or ethnic predispositions, as the prevalence of Syringomyelia is largely governed by the distribution of its underlying causes, such as trauma or congenital structural anomalies. Within the DiseaseMaps.org community, over 700 individuals have shared their unique journeys, highlighting how the experience of living with a syrinx varies greatly depending on the size and location of the fluid-filled cavity within the spinal cord.

Challenges in Data Collection

Accurate tracking is hindered by the fact that many individuals with mild or stable Syringomyelia may never undergo the magnetic resonance imaging (MRI) required for a formal diagnosis. Consequently, most clinical databases likely underestimate the true number of people affected. Real-world platforms like DiseaseMaps.org provide a crucial, complementary perspective by capturing the lived experiences of patients who might otherwise be absent from traditional clinical registries.

Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• Online Mendelian Inheritance in Man (OMIM)